CLINICAL EFFECTS OF MESENCHYMAL STROMAL CELLS IN LYMPHOMA PATIENTS WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Abstract
The clinical and laboratory effects of bone-marrow derived mesenchymal stromal cells (MSC) in patients with malignant lymphomas following autologous hematopoietic stem cell transplantation (auto-HSCT) have been investigated. Co-transplantation of MSC in average dose of 0,178 106/kg was conducted in 74 patients with auto-HSCT. The control group included 83 patients eligible for standard HSCT. We revealed the decreasing of the period of neutropenia and thrombocytopenia when hematopoietic stem cells were co-transplanted with low doses ex vivo expanded autologous MSC. Patients with MSC co-transplantation were differed by more effective early lymphocyte recovery. At the same time MSC co-transplantation did not increase the incidence of infectious complications and cases of renal and. hepatic toxicity. Patients with MSC co-transplantation did not differ from opposite group by 5-year overall survival, but were characterized by significantly better progression-free survival.
About the Authors
E. V. Batorov
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
E. Ya. Shevela
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
I. V. Kryuchkova
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
D. S. Baranova
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
V. V. Sergeevicheva
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
S. A. Sizikova
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
G. Yu. Ushakova
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
A. V. Gilevich
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
A. A. Ostanin
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
E. R. Chernykh
Research Institute of Clinical Immunology SD RAMS
Russian Federation
Russian Federation
References
1. Петровский Я.Л., Курганова Е.В., Тихонова М.А. Характеристика мезенхимальных стромальных клеток костного мозга у больных гемобластозами // Гематология и трансфузиология. — 2008. — Т. 53, № 2. — С. 32 — 38.
2. Angelopoulou M., Novelli E., Grove J.E. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice // Exp Hematol. — 2003. — Vol. 31. — P. 413 — 420.
3. Battiwalla M., Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation // Cytotherapy. — 2009. — Vol. 11, N 5. — P. 503 — 515.
4. Bianco P., Riminucci M., Gronthos S. Bone marrow stromal stem cells: nature, biology, and potential applications // Stem Cells. — 2001. — Vol. 19. — P. 180—192.
5. Bocelli-Tyndall С., Bracci L., Schaeren S. Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15 // Ann Rheum Dis. — 2009. — Vol. 68. — P. 1352—1359.
6. Gordan L.N., Sugrue M.W., Lynch J.W. Correlation of early lymphocyte recovery and progressionfree survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma // Bone Marrow Transplant. — 2003. — Vol. 31. — P. 1009 — 1013.
7. Le Blanc K., Frassoni F., Ball L. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: a phase II study // Lancet. — 2008. — Vol. 371. — P. 1579 — 1586.
8. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E. et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex // Scand. J. Immunol. — 2003. — Vol. 57. — P. 11—20.
9. Majumdar M.K., Thiede M.A., Haynesworth S.E., Bruder S.P. et al. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages // J Hematother Stem Cell Res. — 2000. — Vol. 9. — P. 841 —848.
10. Ning H., Yang F., Jiang M. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study // Leukemia. — 2008. — Vol. 22. — P. 593 — 599.
11. Porrata L.F., Litzow M.R., Inwards D.J. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma // Bone Marrow Transplant. — 2004. — Vol. 33. — P. 291 —298.
12. Salem H.K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status // Stem Cells. — 2010. — Vol. 28. — P. 585 — 596.
13. Sergeevicheva V.V., Shevela E.Y., Sizikova S.A. Autologous mesenchymal stromal cells of hemoblastosis patients efficiently support hematopoietic recovery after stem cell transplantation // Cellular Therapy and Transplantation. — 2010. — Vol. 1, N 4.— P. 98—105.
14. Tyndall A., Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks // Bone Marrow Transplant. — 2009. — Vol. 43. — P. 821 —828.
Review
For citations:
Batorov E.V., Shevela E.Ya., Kryuchkova I.V., Baranova D.S., Sergeevicheva V.V., Sizikova S.A., Ushakova G.Yu., Gilevich A.V., Ostanin A.A., Chernykh E.R. CLINICAL EFFECTS OF MESENCHYMAL STROMAL CELLS IN LYMPHOMA PATIENTS WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Acta Biomedica Scientifica. 2012;(3(2)):33-37. (In Russ.)
Views:
372
Email this article 
